Axon Enterprise vs Curtiss-Wright
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Axon Enterprise and Curtiss-Wright side by side, using each one’s latest annual report. Here is what stands out:
- Curtiss-Wright is the larger business, with $3.5B of revenue in fiscal 2025 against $2.8B for Axon Enterprise.
- Axon Enterprise grew revenue faster (33.5%, against 12.1%).
- Curtiss-Wright kept more of each dollar of sales as operating profit (18.1% operating margin, against −2.2%).
- Curtiss-Wright turned more of its sales into free cash flow (15.8% FCF margin, against 2.7%).
- Curtiss-Wright earned a higher return on the capital invested in it (15.9%, against −2.2%).
- Investors pay more for each dollar of Axon Enterprise’s earnings: a P/E of 176.3x against 32.8x for Curtiss-Wright.
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
Axon Enterprise
AXON
3/11
Revenue growth5-year growthGross margin
Curtiss-Wright
CW
8/11
Operating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | AXON FY25 | CW FY25 |
|---|---|---|
| Size | ||
| Market cap | $35.0B | $17.7B |
| Revenue | $2.8B | $3.5B |
| Free cash flow | $75.1M | $554M |
| Net income | $125M | $484M |
| Growth | ||
| Revenue growth | 33.5% | 12.1% |
| 5-year growth | 32.5% | 7.9% |
| Share count change | 4.9% | −1.9% |
| Profitability | ||
| Gross margin | 59.7% | 37.2% |
| Operating margin | −2.2% | 18.1% |
| Net margin | 4.5% | 13.8% |
| FCF margin | 2.7% | 15.8% |
| Return on capital | −2.2% | 15.9% |
| Return on equity | 4.5% | 19.4% |
| Balance sheet | ||
| Net debt | $104M | $587M |
| Net debt / EBITDA | 4.9x | 0.8x |
| Dividends and buybacks | $0.0M | $500M |
| Valuation & quality | ||
| P/E | 176.3x | 32.8x |
| Piotroski F-score | 6 | 8 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.